Skip to content

Study · Observational study · n = 76 · 2020

6 results

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin.

Uchinuma H, Ichijo M, Harima N, Tsuchiya K

BMC endocrine disorders7 May 2020Cited by 10 (Europe PMC)

PMID32381085 (opens in a new tab)PMCIDPMC7203793 (opens in a new tab)DOI10.1186/s12902-020-0542-5 (opens in a new tab)PepBankPUB-32381085
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundGlucocorticoid (GC)-induced hyperglycemia is characterized by elevated postprandial blood glucose, which commonly requires multiple insulin injections. We investigated whether a long-acting glucagon-like peptide-1 receptor agonist, dulaglutide (Dula), safely improved GC-induced hyperglycemia in inpatients, to reduce insulin injection frequency.MethodsThe data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated. Baseline data were collected at the beginning of GC treatment. The primary outcome in this study was glycemic control, which was compared between the groups using the six-point blood glucose (before and 2 h after each meal) profiles at discharge. The daily injection frequency of injectable drugs at discharge were also compared between groups.ResultsNo specific trend of underlying diseases was observed between the non-Dula and Dula groups. The proportion of patients previously administered with GC pulse therapy was comparable between the two groups. No significant differences were observed between groups, in the starting maintenance GC dose, GC dose at pretreatment of Dula and discharge, and cumulative GC dose during the observation. Six-point blood glucose levels at pretreatment and discharge were comparable between the two groups. However, daily injection frequency of injectable drugs and insulin dose were significantly lower in the Dula group than that in the non-Dula group. No differences were observed in the number of hypoglycemic events, the elevation of serum pancreatic enzyme levels, or gastrointestinal adverse events.ConclusionThese findings suggest that Dula could provide glycemic control while reducing the insulin dose and injection frequency in inpatients with GC-induced hyperglycemia. The occurrence of adverse events such as gastrointestinal symptoms and hypoglycemia did not increase in the Dula-treated patients compared to those not treated, suggesting its safety.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In inpatients with glucocorticoid-induced hyperglycemia, discharge six-point glucose levels were comparable with and without dulaglutide.

    In plain wordsIn hospitalized patients with steroid-related high blood sugar, discharge glucose levels were similar with and without dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeDischarge six-point blood glucose
    Study

    n = 76

    Comparator
    Patients without dulaglutide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Six-point blood glucose levels at pretreatment and discharge were comparable between the two groups.
    2 context sentences
    Summary · context
    The primary outcome in this study was glycemic control, which was compared between the groups using the six-point blood glucose (before and 2 h after each meal) profiles at discharge.
    Summary · context
    The data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated.
  2. 02HumanObservational studyEfficacy outcome

    In inpatients with glucocorticoid-induced hyperglycemia, dulaglutide use was linked to fewer daily injections than care without dulaglutide.

    In plain wordsIn hospitalized patients with steroid-related high blood sugar, dulaglutide use was linked to fewer daily injections than care without dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDaily injection frequency
    Study

    n = 76

    Comparator
    Patients without dulaglutide
    Outcome group
    Device usability · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, daily injection frequency of injectable drugs and insulin dose were significantly lower in the Dula group than that in the non-Dula group.
    2 context sentences
    Summary · context
    The daily injection frequency of injectable drugs at discharge were also compared between groups.
    Summary · context
    The data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated.
  3. 03HumanObservational studyEfficacy outcome

    In inpatients with glucocorticoid-induced hyperglycemia, dulaglutide use was linked to lower insulin doses than care without dulaglutide.

    In plain wordsIn hospitalized patients with steroid-related high blood sugar, dulaglutide use was linked to lower insulin doses than care without dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInsulin dose
    Study

    n = 76

    Comparator
    Patients without dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, daily injection frequency of injectable drugs and insulin dose were significantly lower in the Dula group than that in the non-Dula group.
    1 context sentence
    Summary · context
    The data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated.
  4. 04HumanObservational studySafety outcome

    In inpatients with glucocorticoid-induced hyperglycemia, hypoglycemic event counts did not differ with and without dulaglutide.

    In plain wordsIn hospitalized patients with steroid-related high blood sugar, low blood sugar event counts did not differ with and without dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHypoglycemic events
    Study

    n = 76

    Comparator
    Patients without dulaglutide
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No differences were observed in the number of hypoglycemic events, the elevation of serum pancreatic enzyme levels, or gastrointestinal adverse events.
    1 context sentence
    Summary · context
    The data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated.
  5. 05HumanObservational studySafety outcome

    In inpatients with glucocorticoid-induced hyperglycemia, serum pancreatic enzyme elevation did not differ with and without dulaglutide.

    In plain wordsIn hospitalized patients with steroid-related high blood sugar, pancreatic enzyme elevation did not differ with and without dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerum pancreatic enzyme elevation
    Study

    n = 76

    Comparator
    Patients without dulaglutide
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No differences were observed in the number of hypoglycemic events, the elevation of serum pancreatic enzyme levels, or gastrointestinal adverse events.
    1 context sentence
    Summary · context
    The data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated.
  6. 06HumanObservational studySafety outcome

    In inpatients with glucocorticoid-induced hyperglycemia, gastrointestinal adverse events did not differ with and without dulaglutide.

    In plain wordsIn hospitalized patients with steroid-related high blood sugar, digestive side effects did not differ with and without dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeGastrointestinal adverse events
    Study

    n = 76

    Comparator
    Patients without dulaglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No differences were observed in the number of hypoglycemic events, the elevation of serum pancreatic enzyme levels, or gastrointestinal adverse events.
    1 context sentence
    Summary · context
    The data of hospitalized patients with GC-induced hyperglycemia treated with Dula (Dula group, n = 38) or without (non-Dula group, n = 38) were retrospectively evaluated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.